These results suggest CHRDL2 could serve as a biomarker of poor prognosis in CRC and provide evidence that CHRDL2 acts as an oncogene in human colorectal cancer
Differential expression of CHL2 variants was observed during myoblast and osteoblast differentiation implying a role for this gene in these physiological processes.
We'd like to inform you that we have updated our Privacy Notice to comply with Europe’s new General Data Protection Regulation (GDPR) that applies since 25 May 2018.